Phase 3 Readout

CRMD: Phase 3 Topline: A Phase 3, Prospective, Multicenter, Double-Blind, Randomized, Controlled, Adaptive Study To Demonst

Name: Phase 3 Topline: A Phase 3, Prospective, Multicenter, Double-Blind, Randomized, Controlled, Adaptive Study To Demonst
Start: 2028-01-01
End: 2028-01-01

January 1, 2028. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: January 1, 2028
Company: CorMedix Inc. (CRMD)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Prospective, Multicenter, Double-Blind, Randomized, Controlled, Adaptive Study To Demonst

January 1, 2028

CRMD overview →

Company: CorMedix Inc. (CRMD)
Indication: Central Line Associated Blood Stream Infections (CLABSI)